Cipher Pharmaceuticals Inc (CPH.TO) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Canada · ISIN CA17253X1050

Price
9.48 CAD
Market cap
246.39 m CAD
P/E (2025)
8.86
P/S (2025)
4.80
Dividend yield
0.00 %
Net margin
54.17 %
Return on equity (ROE)
22.07 %
Return on assets (ROA)
17.80 %

Cipher Pharmaceuticals Inc financials

Fiscal year20242025
Revenue33.36 m USD51.33 m USD
Gross profit24.10 m USD33.77 m USD
Operating income7.85 m USD16.80 m USD
EBIT7.85 m USD16.87 m USD
Net income11.55 m USD27.81 m USD
Diluted EPS – continuing operations0.47 USD1.07 USD

Full history since 2004, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.